Shots:

• Alvotech will lead the development- registration- and supply of the biosimilars- while Teva will be exclusively commercializing the products in the US. Alvotech will receive upfront with subsequent milestone payments over the next several years
• The companies will share the profit from the commercialization of the biosimilars. The collaboration leverages Teva’s commercial presence and extensive infrastructure in the US along with Alvotech’s experience and state-of-the-art biologics manufacturing
• The collaboration will improve patient access for high-quality biosimilar medicines in the US

­ Ref: Teva | Image: PharmaShots